High-Sensitivity On-Bead ELISA Assay for Cancer Liquid Biopsy Immuno-Diagnostics

Name Cat# Price (1ml, USD) Add to cart
MagVigen™ – PD-L1 On-Bead ELISA Kit
Product Sheet
KE7101 $560
for 96 assays
MagVigen™ – HER2 On-Bead ELISA Kit
Product Sheet
KE7102 $560
for 96 assays
MagVigen™ – EGFR On-Bead ELISA Kit
Product Sheet
KE7103 $560
for 96 assays
MagVigen™ – CEA On-Bead ELISA Kit KE7104 $560
for 96 assays
MagVigen™ – VEGF On-Bead ELISA Kit KE7105 $560
for 96 assays
MagVigen™ – TNF-α On-Bead ELISA Kit KE7106 $560
for 96 assays
MagVigen™ – TGF-β On-Bead ELISA Kit KE7107 $560
for 96 assays
MagVigen™ – IFN-γ On-Bead ELISA Kit KE7108 $560
for 96 assays
MagVigen™ – InterLeukin- On-Bead ELISA Kits KE7109
for 96 assays

Magnetic nanoparticles are an increasingly common feature in diagnostics. With their ability to disperse evenly throughout a medium, the reactive surface area of functionalized nanoparticles exhibit superior kinetics in capturing target analytes with high efficiency. NVIGEN’s nanoparticle-based ELISA assays are thus rapid, highly sensitive tests with shorter incubation times that enable a smoother workflow, provide superior results, and support multiplex assays.


Figure 1. Overview of On-Beads ELISA Assay.


  • KE7101 MagVigen™ – PD-L1 On-Bead ELISA Kit
  • KE7102 MagVigen™ – Her-2 On-Bead ELISA Kit
  • KE7103 MagVigen™ – EGFR On-Bead ELISA Kit

On-Beads-ELISA Assay General Protocol:


Figure 2. Basic Workflow for On-Bead ELISA Assay.

  1. Antigen capture: Mix sample with antibody-conjugated beads, which will rapidly capture analyte such as sPD-L1.
  2. Wash: Place plate on an NVIGEN magnetic plate (cat#A20008) and wash plasma and other proteins from the plate. The NVIGEN magnetic plate is designed to magnetize the beads into a pellet so that the supernatant can be easily removed.
  3. Incubate with enzyme-bound detection antibody: Mix detection antibody in assay diluent and incubate with the beads.
  4. Wash: Wash excess enzyme from the plate, again using the NVIGEN magnetic plate to pellet the beads between wash steps.
  5. Add Detection Solution: Add detection solution, pipet up and down to mix, incubate for 15 minutes for the reaction to proceed.
  6. Transfer detection solution to new plate, read on plate reader: Transfer the supernatant to a clean plate and read the results using a standard plate reader.


Our bead-based PDL1 assay notably exhibits over 6x the sensitivity of a standard ELISA in which capture antibodies are adsorbed onto a plate surface. Additionally, due to the optimal bead kinetics, our assay can be performed in a fraction of the time compared to competing assays, with a lower limit of detection at 0.1 ng/mL.


Figure 3. On-Bead Elisa PD-L1 Assay Performance.

Comparison of standard on-plate versus on-bead ELISAs done in human plasma. On-Bead ELISAs demonstrate superior linearity, signal, and sensitivity. Low-end detection threshold is approximately 100 pg/mL with 200 uL of human plasma sample.

PD-L1 on-bead-vs-on-plate

Figure 4. PD-L1 assay performance, on-plate vs. on-bead.

EGFR on-bead-vs-on-plate

Figure 5. EGFR assay performance, on-plate vs. on-bead.

HER2 on-bead-vs-on-plate

Figure 6. HER2 assay performance, on-plate vs. on-bead.

CEA on-bead-vs-on-plate

Figure 7. CEA assay performance, on-plate vs. on-bead. CEA (Cancer Embryonic Antigen), more specifically known as CEACAM5 (CarcinoEmbryonic Antigen-related Cell Adhesion Molecule 5), or CD66e, is a biomarker of a multitude of cancers, particularly colorectal cancers1. Its role in breast cancer is an active field of research2. Progressively elevated levels of CEA have been found to correlate with both the progressive stage as well as the grade of breast cancer3.


  1. Beauchemin N, Arabzadeh A (December 2013). “Carcinoembryonic antigen-related cell adhesion molecules (CEACAMs) in cancer progression and metastasis“. Cancer and Metastasis Reviews. Volume 32 p643–671.
  2. Shao Y, Sun X (2015). “Elevated Levels of Serum Tumor Markers CEA and CA15-3 Are Prognostic Parameters for Different Molecular Subtypes of Breast Cancer“. PLoS ONE 10(7).
  3. Al-Nafakh Z, Al-Dujaili (2020). “Assessment of Cancer Embryonic Antigen (CEA) Biomarker in Women with Breast Cancer Disease“. AIP Conference Proceedings 2290.